Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1245.50
-24.30 (-1.91%)
< Home < Back

USFDA completes audit at Dr. Reddy’s API Mirfield plant in UK

Date: 16-09-2017

The US Food and Drug Administration (USFDA) has completed the inspection at Dr. Reddy’s Laboratories’ API Mirfield Plant, United Kingdom on September 15, 2017. The company has been issued a Form 483 with three observations.

Recently, Regulatory Authority of Germany (Regierung von Oberbayern) had concluded an audit of Dr. Reddy’s Laboratories’ Formulations manufacturing facility in Duvvada, Vishakapatnam, with zero critical and six major observations.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.